Download PDF
Semin Neurol 2018; 38(05): 505-514
DOI: 10.1055/s-0038-1667382
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Ethical Considerations in Neurogenetic Testing

Xiaowei W. Su
1   Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
,
Zachary Simmons
2   Departments of Neurology and Humanities, Pennsylvania State University College of Medicine, Hershey, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
15 October 2018 (online)

    Permissions and Reprints

Abstract

Recent advances in the genetics of neurologic diseases coupled with improvements in sensitivity and specificity are making genetic testing an increasingly important part of diagnosis and management for neurologists. However, the complex nature of genetic testing, the nuances of multiple result types, and the short- and long-term consequences of genetic diagnoses raise important ethical issues for the clinician. Neurologists must balance the ethical principles of beneficence and nonmaleficence, on the one hand, with patient autonomy on the other hand, when ordering such tests by facilitating shared decision making, carrying out their fiduciary responsibilities to patients, and ensuring that patients have adequate counseling to make informed decisions. This review summarizes ethical issues related to genetic testing for neurologic diseases, with a focus on clinical practice. Informed consent for genetic testing of patients and asymptomatic at-risk family members is discussed. The roles and responsibilities of physicians as genetic counselors are reviewed, including the framing of incidental findings and variants of unknown significance that impact individuals' decisions about whether to pursue genetic testing and what results they wish to know. Disclosure and its consequences for the patient are placed within an ethical framework to permit a better understanding of why genetic testing is different from most other diagnostic testing ordered by physicians. The review ends with clinical vignettes that attempt to place ethical principles into familiar clinical settings involving physicians, patients and their families.

Keywords

genetic testing - ethics - informed consent - genetic counseling
 

  • References

  • 1 Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50 (03) 509-517
    CrossrefPubMedGoogle Scholar
  • 2 Wetterstrand K. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at: http://www.genome.gov/sequencingcostsdata . Accessed March 1, 2018
    PubMedGoogle Scholar
  • 3 Córdoba M, Rodriguez-Quiroga SA, Vega PA. , et al. Whole exome sequencing in neurogenetic odysseys: an effective, cost- and time-saving diagnostic approach. PLoS One 2018; 13 (02) e0191228
    CrossrefPubMedGoogle Scholar
  • 4 Grady C. Enduring and emerging challenges of informed consent. N Engl J Med 2015; 372 (09) 855-862
    CrossrefPubMedGoogle Scholar
  • 5 Vinther-Jensen T, Larsen IU, Hjermind LE. , et al. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease. Orphanet J Rare Dis 2014; 9: 114
    CrossrefPubMedGoogle Scholar
  • 6 Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65 (04) 586-590
    CrossrefPubMedGoogle Scholar
  • 7 Dunn LB, Nowrangi MA, Palmer BW, Jeste DV, Saks ER. Assessing decisional capacity for clinical research or treatment: a review of instruments. Am J Psychiatry 2006; 163 (08) 1323-1334
    CrossrefPubMedGoogle Scholar
  • 8 Morgenstern J, Hegele RA, Nisker J. Simple genetics language as source of miscommunication between genetics researchers and potential research participants in informed consent documents. Public Underst Sci 2015; 24 (06) 751-766
    CrossrefPubMedGoogle Scholar
  • 9 Chandra A, Johri A, Beal MF. Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov Disord 2014; 29 (03) 285-293
    CrossrefPubMedGoogle Scholar
  • 10 Palmer AM. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 2011; 32 (03) 141-147
    CrossrefPubMedGoogle Scholar
  • 11 Saeed M, Yang Y, Deng HX. , et al. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology 2009; 72 (19) 1634-1639
    CrossrefPubMedGoogle Scholar
  • 12 Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; 3 (03) CD001447
    PubMedGoogle Scholar
  • 13 Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16 (07) 505-512
    CrossrefPubMedGoogle Scholar
  • 14 Fan HC, Chen SJ, Harn HJ, Lin SZ. Parkinson's disease: from genetics to treatments. Cell Transplant 2013; 22 (04) 639-652
    CrossrefPubMedGoogle Scholar
  • 15 Burke W, Pinsky LE, Press NA. Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet 2001; 106 (03) 233-240
    CrossrefPubMedGoogle Scholar
  • 16 Lefebvre S, Bürglen L, Reboullet S. , et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80 (01) 155-165
    CrossrefPubMedGoogle Scholar
  • 17 D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis 2011; 6: 71
    CrossrefPubMedGoogle Scholar
  • 18 Finkel RS, Mercuri E, Darras BT. , et al; ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377 (18) 1723-1732
    CrossrefPubMedGoogle Scholar
  • 19 Ross LF, Clarke AJ. A historical and current review of newborn screening for neuromuscular disorders from around the world: lessons for the United States. Pediatr Neurol 2017; 77: 12-22
    CrossrefPubMedGoogle Scholar
  • 20 Goate A, Chartier-Harlin MC, Mullan M. , et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349 (6311): 704-706
    CrossrefPubMedGoogle Scholar
  • 21 Sherrington R, Rogaev EI, Liang Y. , et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375 (6534): 754-760
    CrossrefPubMedGoogle Scholar
  • 22 Levy-Lahad E, Wasco W, Poorkaj P. , et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269 (5226): 973-977
    CrossrefPubMedGoogle Scholar
  • 23 Goldman JS, Hahn SE, Catania JW. , et al; American College of Medical Genetics and the National Society of Genetic Counselors. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011; 13 (06) 597-605
    CrossrefPubMedGoogle Scholar
  • 24 Corder EH, Saunders AM, Strittmatter WJ. , et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261 (5123): 921-923
    CrossrefPubMedGoogle Scholar
  • 25 Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging 2011; 32 (05) 778-790
    CrossrefPubMedGoogle Scholar
  • 26 The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72 (06) 971-983
    CrossrefPubMedGoogle Scholar
  • 27 Walker FO. Huntington's disease. Lancet 2007; 369 (9557): 218-228
    CrossrefPubMedGoogle Scholar
  • 28 Timman R, Maat-Kievit A, Brouwer-DudokdeWit C, Zoeteweij M, Breuning MH, Tibben A. Testing the test--why pursue a better test for Huntington disease?. Am J Med Genet B Neuropsychiatr Genet 2003; 117B (01) 79-85
    CrossrefPubMedGoogle Scholar
  • 29 MacLeod R, Tibben A, Frontali M. , et al; Editorial Committee and Working Group ‘Genetic Testing Counselling’ of the European Huntington Disease Network. Recommendations for the predictive genetic test in Huntington's disease. Clin Genet 2013; 83 (03) 221-231
    CrossrefPubMedGoogle Scholar
  • 30 Polymeropoulos MH, Lavedan C, Leroy E. , et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276 (5321): 2045-2047
    CrossrefPubMedGoogle Scholar
  • 31 Zimprich A, Biskup S, Leitner P. , et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44 (04) 601-607
    CrossrefPubMedGoogle Scholar
  • 32 Kitada T, Asakawa S, Hattori N. , et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392 (6676): 605-608
    CrossrefPubMedGoogle Scholar
  • 33 Valente EM, Abou-Sleiman PM, Caputo V. , et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304 (5674): 1158-1160
    CrossrefPubMedGoogle Scholar
  • 34 Puschmann A. Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013; 19 (04) 407-415
    CrossrefPubMedGoogle Scholar
  • 35 Lill CM. Genetics of Parkinson's disease. Mol Cell Probes 2016; 30 (06) 386-396
    CrossrefPubMedGoogle Scholar
  • 36 Healy DG, Falchi M, O'Sullivan SS. , et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7 (07) 583-590
    CrossrefPubMedGoogle Scholar
  • 37 Byrne S, Walsh C, Lynch C. , et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82 (06) 623-627
    CrossrefPubMedGoogle Scholar
  • 38 Renton AE, Majounie E, Waite A. , et al; ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72 (02) 257-268
    CrossrefPubMedGoogle Scholar
  • 39 Rosen DR, Siddique T, Patterson D. , et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362 (6415): 59-62
    CrossrefPubMedGoogle Scholar
  • 40 Vance C, Rogelj B, Hortobágyi T. , et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323 (5918): 1208-1211
    CrossrefPubMedGoogle Scholar
  • 41 Sreedharan J, Blair IP, Tripathi VB. , et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319 (5870): 1668-1672
    CrossrefPubMedGoogle Scholar
  • 42 Chia R, Chiò A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018; 17 (01) 94-102
    CrossrefPubMedGoogle Scholar
  • 43 ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet Med 2012; 14 (08) 759-761
    CrossrefPubMedGoogle Scholar
  • 44 Pletcher BA, Toriello HV, Noblin SJ. , et al. Indications for genetic referral: a guide for healthcare providers. Genet Med 2007; 9 (06) 385-389
    PubMedGoogle Scholar
  • 45 Secretary's Advisory Committee on Genetics Health and Society. Report on Genetics Education and Training: February 2011 . Available at: https://www.genome.gov/pages/careers/healthprofessionaleducation/sacghs-educationreport2011.pdf . Accessed March 1, 2018
    PubMed
  • 46 Bowdin S, Gilbert A, Bedoukian E. , et al. Recommendations for the integration of genomics into clinical practice. Genet Med 2016; 18 (11) 1075-1084
    CrossrefPubMedGoogle Scholar
  • 47 Su X, Kang PB, Russell JA, Simmons Z. Ethical issues in the evaluation of adults with suspected genetic neuromuscular disorders. Muscle Nerve 2016; 54 (06) 997-1006
    CrossrefPubMedGoogle Scholar
  • 48 Skirton H, Goldsmith L, Jackson L, O'Connor A. Direct to consumer genetic testing: a systematic review of position statements, policies and recommendations. Clin Genet 2012; 82 (03) 210-218
    CrossrefPubMedGoogle Scholar
  • 49 Allyse MA, Robinson DH, Ferber MJ, Sharp RR. Direct-to-consumer testing 2.0: emerging models of direct-to-consumer genetic testing. Mayo Clin Proc 2018; 93 (01) 113-120
    CrossrefPubMedGoogle Scholar
  • 50 Ensenauer RE, Michels VV, Reinke SS. Genetic testing: practical, ethical, and counseling considerations. Mayo Clin Proc 2005; 80 (01) 63-73
    CrossrefPubMedGoogle Scholar
  • 51 Smith CO, Lipe HP, Bird TD. Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol 2004; 61 (06) 875-880
    CrossrefPubMedGoogle Scholar
  • 52 Almqvist EW, Bloch M, Brinkman R, Craufurd D, Hayden MR. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999; 64 (05) 1293-1304
    CrossrefPubMedGoogle Scholar
  • 53 Baum A, Friedman AL, Zakowski SG. Stress and genetic testing for disease risk. Health Psychol 1997; 16 (01) 8-19
    CrossrefPubMedGoogle Scholar
  • 54 Tibben A, Vegter-van der Vlis M, Skraastad MI. , et al. DNA-testing for Huntington's disease in The Netherlands: a retrospective study on psychosocial effects. Am J Med Genet 1992; 44 (01) 94-99
    CrossrefPubMedGoogle Scholar
  • 55 Krishnan S, York MK, Backus D, Heyn PC. Coping with caregiver burnout when caring for a person with neurodegenerative disease: a guide for caregivers. Arch Phys Med Rehabil 2017; 98 (04) 805-807
    CrossrefPubMedGoogle Scholar
  • 56 Godard B, Hurlimann T, Letendre M, Egalité N. ; INHERIT BRCAs. Guidelines for disclosing genetic information to family members: from development to use. Fam Cancer 2006; 5 (01) 103-116
    CrossrefPubMedGoogle Scholar
  • 57 President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Screening and Counseling for Genetic Conditions: The Ethical, Social, and Legal Implications of Genetic Screening, Counseling, and Education Programs. Washington, DC: U.S. Government Printing Office; 1983
    Google Scholar
  • 58 Institute of Medicine. Assessing Genetic Risks: Implications for Health and Social Policy. Washington, DC: The National Academies Press; 1994
    Google Scholar
  • 59 Amendola LM, Dorschner MO, Robertson PD. , et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res 2015; 25 (03) 305-315
    CrossrefPubMedGoogle Scholar
  • 60 Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med 2015; 17 (07) 587-595
    PubMedGoogle Scholar
  • 61 Green RC, Berg JS, Grody WW. , et al; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15 (07) 565-574
    CrossrefPubMedGoogle Scholar
  • 62 Clarke AJ. Managing the ethical challenges of next-generation sequencing in genomic medicine. Br Med Bull 2014; 111 (01) 17-30
    CrossrefPubMedGoogle Scholar
  • 63 Hofmann B. Incidental findings of uncertain significance: to know or not to know--that is not the question. BMC Med Ethics 2016; 17: 13
    CrossrefPubMedGoogle Scholar
  • 64 van der Tol L, Smid BE, Poorthuis BJ. , et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 2014; 51 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 65 Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 2017; 11: 533-545
    CrossrefPubMedGoogle Scholar
  • 66 European Society of Human Genetics. Genetic testing in asymptomatic minors: Recommendations of the European Society of Human Genetics. Eur J Hum Genet 2009; 17 (06) 720-721
    PubMedGoogle Scholar
  • 67 Ross LF, Saal HM, David KL, Anderson RR. ; American Academy of Pediatrics; American College of Medical Genetics and Genomics. Technical report: Ethical and policy issues in genetic testing and screening of children. Genet Med 2013; 15 (03) 234-245
    PubMedGoogle Scholar
  • 68 Botkin JR, Belmont JW, Berg JS. , et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 2015; 97 (01) 6-21
    CrossrefPubMedGoogle Scholar
  • 69 Rohrer JD, Isaacs AM, Mizielinska S. , et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 2015; 14 (03) 291-301
    CrossrefPubMedGoogle Scholar
  • 70 Bertrand A, Wen J, Rinaldi D. , et al; Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (PREV-DEMALS) Study Group. Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years. JAMA Neurol 2018; 75 (02) 236-245
    CrossrefPubMedGoogle Scholar
  • 71 Raal FJ, Santos RD, Blom DJ. , et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375 (9719): 998-1006
    CrossrefPubMedGoogle Scholar
  • 72 Pellitteri PK, Rinaldo A, Myssiorek D. , et al. Paragangliomas of the head and neck. Oral Oncol 2004; 40 (06) 563-575
    CrossrefPubMedGoogle Scholar
  • 73 Olivier M, Goldgar DE, Sodha N. , et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63 (20) 6643-6650
    PubMedGoogle Scholar
  • 74 Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 1996; 81 (07) 2642-2646
    PubMedGoogle Scholar
  • 75 Asthagiri AR, Parry DM, Butman JA. , et al. Neurofibromatosis type 2. Lancet 2009; 373 (9679): 1974-1986
    CrossrefPubMedGoogle Scholar
  • 76 Abel TW, Baker SJ, Fraser MM. , et al. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 2005; 64 (04) 341-349
    CrossrefPubMedGoogle Scholar
  • 77 Lin P, O'Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol 2009; 148 (02) 192-198
    CrossrefPubMedGoogle Scholar
  • 78 Mizuguchi M, Takashima S. Neuropathology of tuberous sclerosis. Brain Dev 2001; 23 (07) 508-515
    CrossrefPubMedGoogle Scholar
  • 79 Lonser RR, Glenn GM, Walther M. , et al. von Hippel-Lindau disease. Lancet 2003; 361 (9374): 2059-2067
    CrossrefPubMedGoogle Scholar